Psychedelic Research May Support Unprecedented End-of-Life Care for Patients With Cancer
June 1st 2023Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.
Read More
Lisocabtagene Maraleucel Delivers Deep, Durable Efficacy in Chronic Lymphocytic Leukemia
May 30th 2023Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.
Read More